Naturally occurring human sequences such as BRCA1 and BRCA2 are no longer patentable

The Supreme Court has decided that naturally occurring human  sequences are no longer patentable.  This case  was on the use of the gene patents for  BRCA1 and BRCA2 genes in the diagnosis of inherited breast or ovarian cancer.  However, the court indicated that  derived  cDNA sequences may be patentable.   This decision has profound general  implications for the Biotech industry and is discussed in this article